Ridge Bio Launches with $25M to Redefine Enzyme and Drug Design

In September 2025, Ridge Biotechnologies stepped out of stealth with a $25 million oversubscribed seed round, one of the largest early financings for a European biotech that year.

Ridge is building a platform that fuses machine learning with expansive biochemical datasets to design precision enzymes. These are aimed at drug targets often considered too complex or inaccessible for conventional approaches.

Alongside this, the company is developing targeted delivery systems for genetic medicines—including siRNA, mRNA, and CAR-T—designed to activate therapies only in the tissues where they are needed.

The team behind Ridge brings together scientists and entrepreneurs with backgrounds spanning enzymology, chemical biology, and AI. Their ambition is to create a new class of medicines that go beyond the limitations of small molecules or antibody-based treatments.

Sources:
Ridge Biotechnologies
Yahoo!Finance
Business Wire
First Word Pharma

J.V.